ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ — Poster
16LB — Late-breaking Novo Nordisk (NVO) extension data presented
today at the 70th Annual Scientific Sessions of the American
Diabetes Association (ADA) showed that once-daily Victoza® in
combination with metformin produced sustained and significantly
greater reductions in A1c, body weight and fasting plasma glucose
(FPG) than Januvia® plus metformin at 52 weeks.
Key findings from the study include:
- Patients treated with 1.2 mg and 1.8 mg of Victoza®
experienced greater reductions in A1c than those treated with
Januvia® 100 mg (-1.3% and -1.5% versus -0.9%) - Victoza® provided greater weight loss versus patients
treated with Januvia® (2.8 kg [6.16 lbs] and 3.7 kg [8.14 lbs] for 1.2 mg and 1.8 mg respectively, 1.2 kg [2.64 lbs] for
Januvia®) - Victoza® provided greater change from baseline FPG readings
than those treated with Januvia® (-1.7 mmol/L and -2.0 mmol/L
for 1.2 mg and 1.8 mg respectively, versus -0.6 mmol/L) - Patients treated with Victoza® 1.8 mg reported
significantly greater treatment satisfaction than those treated
with Januvia®
“What is so encouraging about these data is that Victoza® at
both doses was more effective than Januvia® at achieving blood
sugar control in people with type 2 diabetes over a period of one
year. Patients who began the trial with higher A1c levels
achieved greater reductions in A1c with treatment with
Victoza®,” said Dr. Richard
Pratley, of the Diabetes and Metabolism Translational
Medicine Unit, University of Vermont
College of Medicine, Burlington.
“Altho
‘/>”/>
